Esketamine Intranasal

Drug Overview

Esketamine Intranasal, delivered via an intranasal spray, represents one of the most significant pharmacological breakthroughs in Psychiatry in recent decades. It belongs to the NMDA Receptor Antagonist Drug Class. Unlike traditional antidepressants that take weeks to alter serotonin or dopamine levels, esketamine works on an entirely different neurotransmitter system to provide rapid, sometimes immediate, relief from severe depressive symptoms and acute suicidal ideation.

• Generic Name / Active Ingredient: Esketamine hydrochloride
• US Brand Names: Spravato
• Route of Administration: Intranasal (Nasal Spray)
• FDA Approval Status: FDA-Approved under a highly restricted REMS (Risk Evaluation and Mitigation Strategy) program.

What Is It and How Does It Work? (Mechanism of Action)

Esketamine is the “S” enantiomer (a specific mirror-image molecule) of ketamine, an anesthetic used in hospitals for over half a century. It functions as a rapid-acting Targeted Therapy for the brain’s glutamate system.

Glutamate is the brain’s primary excitatory neurotransmitter—the chemical responsible for driving electrical signals forward and promoting neuroplasticity. Chronic, severe depression has been shown to physically wither the synaptic connections (dendrites) between brain cells, particularly in the prefrontal cortex and hippocampus.

At the molecular level, esketamine acts as a non-competitive antagonist at the N-methyl-D-aspartate (NMDA) receptor. When esketamine binds to and blocks this receptor, it triggers a sudden, massive surge in glutamate release in the brain.

This glutamate surge activates a secondary receptor called AMPA. The activation of AMPA receptors immediately kicks off a complex cellular cascade that drastically increases the production of Brain-Derived Neurotrophic Factor (BDNF). This massive release of BDNF acts like high-powered fertilizer for the brain, rapidly forcing the growth of new synaptic connections. This process, which physically repairs the brain damage caused by chronic depression, is why esketamine can lift mood in hours rather than weeks.

FDA-Approved Clinical Indications

Primary Psychiatric Indications

• Treatment-Resistant Depression (TRD): Approved for use in adults who have not responded adequately to at least two different oral antidepressants of adequate dose and duration. It must be used in conjunction with an oral antidepressant.
• Major Depressive Disorder with Acute Suicidal Ideation or Behavior: Approved for the rapid reduction of depressive symptoms in adults presenting to the clinic with an active, acute risk of suicide.

Off-Label / Neurological Indications

• Bipolar Depression: While officially approved for unipolar Major Depressive Disorder, specialists increasingly utilize esketamine off-label to treat severe, treatment-resistant depressive episodes in patients with Bipolar Disorder, usually ensuring the patient is also taking a mood stabilizer (like lithium) to prevent a manic switch.
• Severe Post-Traumatic Stress Disorder (PTSD): Investigated off-label for rapidly reducing hyperarousal and intrusive thoughts in severe trauma patients.

Dosage and Administration Protocols

Crucial Note: Esketamine is never dispensed to a patient for home use. It must be administered in a certified medical office where the patient is observed for at least two hours post-dose.

Special Population Adjustments:

• Hepatic (Liver) Insufficiency: Patients with moderate hepatic impairment may require lower doses. It is not recommended for severe hepatic impairment.
• Elderly Patients: Starting doses are typically lower (e.g., 28 mg) to minimize the risk of severe blood pressure spikes and intense dissociation.

Clinical Efficacy and Research Results

Clinical data (2020-2026) confirms that esketamine fills a critical gap in emergency psychiatric care: the need for rapid onset.

• Rapid Response: In trials measuring the Montgomery-Åsberg Depression Rating Scale (MADRS), patients often report a statistically significant reduction in depressive symptoms within 2 to 24 hours of the first dose, compared to the 4 to 6 weeks required for oral SSRIs.
• Suicidality: In studies of patients hospitalized for acute suicidality, those receiving esketamine demonstrated a rapid resolution of suicidal ideation within 4 hours, significantly reducing the need for prolonged inpatient psychiatric hospitalization.
• Long-Term Remission: Maintenance trials demonstrate that patients who achieve remission on esketamine and continue maintenance dosing delay depressive relapse by over 50% compared to those transitioned to a placebo nasal spray.

Safety Profile and Side Effects

BLACK BOX WARNING: SEDATION; DISSOCIATION; ABUSE AND MISUSE; AND SUICIDAL THOUGHTS AND BEHAVIORS

• Sedation & Dissociation: Patients are at risk for sedation and dissociation after administration and must be monitored by a healthcare provider for at least 2 hours at each treatment session.
• Abuse & Misuse: Esketamine is a Schedule III controlled substance. It carries a risk of abuse, misuse, and psychological dependence.
• REMS Program: Because of these risks, Spravato is only available through a restricted program called the Spravato REMS.

Common Side Effects (>10%)

• Dissociation: A feeling of detachment from reality, floating, or a distorted sense of time and space (the most common and expected side effect).
• Dizziness and vertigo
• Nausea and vomiting
• Lethargy and severe sedation
• Temporary spike in blood pressure

Serious Adverse Events

• Hypertensive Crisis: Esketamine can cause sudden, massive spikes in blood pressure within the first 40 minutes of administration, which can lead to stroke or cardiovascular events in at-risk patients.
• Cognitive Impairment: Long-term, high-dose use of ketamine analogues has been associated with memory impairment, though structured, clinical dosing aims to minimize this risk.
• Cystitis: Rare reports of ulcerative cystitis (severe bladder inflammation and pain) associated with long-term, high-dose ketamine use.

Management Strategies

• For Dissociation: The clinic environment is kept quiet, dim, and calm. Dissociation typically peaks at 40 minutes and resolves entirely by the 2-hour mark.
• For Blood Pressure: The clinic must check blood pressure before dosing, at 40 minutes, and before discharging the patient. If a hypertensive crisis occurs, emergency anti-hypertensive protocols are initiated.
• For Nausea: Patients are instructed not to eat for 2 hours, or drink liquids for 30 minutes, prior to the session.

Research Areas

Esketamine is currently at the absolute forefront of psychiatric research (2020-2026) regarding Neuroplasticity. While it is not a stem cell therapy, functional MRI (fMRI) studies are actively mapping how the glutamate surge physically alters the brain. Researchers are investigating how this rapid synaptogenesis (the growth of new cellular connections) can be paired with intense, targeted psychotherapy (often called Ketamine-Assisted Psychotherapy) while the brain is in a highly plastic, adaptable state. The goal is to use the chemical catalyst of the drug to “rewire” the traumatic memories and rigid, depressive thought loops embedded in the patient’s psychology.

Disclaimer: This information is a research hypothesis, not established clinical facts. It may be biologically plausible, but it is not yet validated for routine medical practice.

Patient Management and Practical Recommendations

Pre-Treatment Tests:

• Cardiovascular Baseline: Thorough screening for aneurysms, uncontrolled hypertension, or recent vascular events (stroke, heart attack). Esketamine is strictly contraindicated in patients with aneurysmal vascular disease.
• Psychiatric Screening: Rule out a history of psychotic disorders (like schizophrenia), as the drug can trigger severe hallucinations. Ensure bipolar patients are taking a mood stabilizer.

Precautions During Treatment:

• The patient cannot drive or operate machinery until the day after the treatment session, following a restful sleep.
• The clinic must have emergency equipment (oxygen, anti-hypertensive drugs) readily available.

Do’s and Don’ts:

• DO arrange for a trusted friend, family member, or medical transport to drive you home after every single session.
• DO blow your nose before using the nasal spray device.
• DON’T eat a heavy meal within 2 hours of your appointment to prevent severe nausea and vomiting.
• DON’T consume alcohol or take benzodiazepines (like Xanax) on the day of treatment without explicit doctor approval, as they dangerously multiply the sedative effects and can dull the drug’s efficacy.

Legal Disclaimer

The medical information provided in this guide is intended for educational and informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. It is not a substitute for a comprehensive consultation with a qualified healthcare provider. Esketamine must be administered in a certified clinical setting due to significant safety risks. Always seek the advice of your physician regarding any medical condition, treatment options, or drug interactions. Do not disregard professional medical advice or delay seeking it based on the contents of this article.